搜索结果

Search Results for " akt-in-11 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T63653	AKT-IN-11
	AKT-IN-11 是有效的抗人肝癌 Bel-7402 细胞株抗菌剂之一 (IC50: 1.15 μM)。
T4444	A-674563 HCl (552325-73-2(free base))	ERK; Akt; PKA; CDK; PKC	Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors
	A-674563 HCl (552325-73-2(free base)) 是一种口服的、ATP 竞争性的、可逆的 Akt 抑制剂（Akt1 的 Ki：11 nM）。它对 PKA 和 Cdk2 具有抑制活性（IC50：16/46 nM），但对 Akt1 的选择性比 CMGC、CAMK 和 TK 家族中的其他激酶高 10 至 >1800 倍。
T62408	PI3Kδ-IN-11
	PI3Kδ-IN-11 是一种高效的、选择性的 PI3Kδ 抑制剂 (IC50: 27.5 nM)，能够剂量依赖性地阻断 PI3K/Akt 通路的活性。PI3Kδ-IN-11 能够用于 B 细胞或 T 细胞相关的恶性肿瘤研究。
T63528	HSP90-IN-11
	HSP90-IN-11 是 HSP90 的有效抑制剂，诱导亚 G1 期群体的显着积累。 HSP90-IN-11 具有与 AUY-922 (Luminespib) 相当的有效 HSP90α 抑制作用。在 CRC 和 NSCLC 细胞中，HSP90-IN-11 具有显着的抗增殖活性，在两位数 nM 范围内。HSP90-IN-11 能够快速降解 NSCLC 细胞中客户蛋白 EGFR 和 Akt 。
T36085	PKI-179 hydrochloride
	PKI-179 is an orally bioavailable dual inhibitor of PI3K and mammalian target of rapamycin (mTOR). In an in vitro enzymatic assay, it potently inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively), two common PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively), and mTOR (IC50 = 0.42 nM). PKI-179 is selective for PI3K and mTOR over a panel of 361 other kinases at IC50 values up to 50 μM, hERG (IC50 > 30 μM), and cytochrome P450 (CYP) isoforms (IC5...
T35527	PI3Kα-IN-4 PI3Kα-IN-4
	PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity[1]. PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC50s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays[1].PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC50s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays[1]. PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit t...